Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This partially randomized phase I/II trial studies the side effects and best dose of
cediranib maleate when given together with or without lenalidomide and to see how well they
work in treating patients with thyroid cancer. Cediranib maleate may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the
growth of thyroid cancer by blocking blood flow to the tumor. It is not yet known whether
cediranib maleate is more effective when given together with lenalidomide in treating thyroid
cancer.